Severe COVID-19

Indication: Hospitalized patients with Severe COVID-19
Title: Phase 2 Randomized Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor in Patients with Severe COVID-19
Drug: Selinexor

This study has been discontinued as of August 2020

Please visit clinicaltrials.gov for more information about this study

Rights

Drug: Selinexor

Phase 1Phase 2Phase 3Commercial
Phase 1
Phase 2
Phase 3
Commercial